

**EUROPEAN  
CURRICULUM VITAE  
FORMAT**



**PERSONAL INFORMATION**

Name **LOMBARDI GIUSEPPE**

Address VENETO INSTITUTE OF ONCOLOGY  
MEDICAL ONCOLOGY 1 UNIT  
VIA GATTAMELATA 64  
35128 PADUA, ITALY

E-mail [giuseppe.lombardi@iov.veneto.it](mailto:giuseppe.lombardi@iov.veneto.it)

Nationality Italian

Date of birth MARCH, 13<sup>TH</sup>, 1980

**WORK EXPERIENCE**

- Dates (from – to) From February 2010 to date
  - Name and address of employer Medical Oncology 1 Unit  
Istituto Oncologico Veneto, IRCCS, Padova  
Public Hospital
  - Type of business or sector Medical Oncologist
  - Occupation or position held Medical Treatment of Cancer Patients, in particular with Brain Tumors
  - Main activities and responsibilities
- 
- Dates (from – to) January 2011- March 2014
  - Name and address of employer University of Padua -  
Public Hospital
  - Type of business or sector PhD on Oncology and Oncological Surgery
  - Occupation or position held Research of a diagnostic biomarker in brain glioma patients
  - Main activities and responsibilities
- 
- Dates (from – to) December 2012-February 2013
  - Name and address of employer Department of Neuro-Oncology  
Hospital Salpetriere, University of Paris VI, Paris (France)
  - Type of business or sector Public Hospital
  - Occupation or position held Fellow
  - Main activities and responsibilities Clinical and Research Activity on Brain Tumors
- 
- Dates (from – to) January 2009 – March 2009
  - Name and address of employer Memorial Sloan Kettering Cancer Center – New York (USA)
  - Type of business or sector Neuro- Oncology
  - Occupation or position held Fellow
  - Main activities and responsibilities Research project on Brain Tumors
- 
- Dates (from – to) January 2006 – January 2010
  - Name and address of employer Resident in Medical Oncology  
Padua University
  - Type of business or sector Assistance in medical management and clinical research in solid tumors
  - Occupation or position held

## RESEARCH EXPERIENCE

- Dates (from – to)
- Name and address of Organization

- Occupation or position held
- Main activities and responsibilities

- Dates (from – to)
- Name and address of employer
  - Type of business or sector
  - Occupation or position held
- Main activities and responsibilities

2010-present

Industry Sponsored Trials or Academic trials (European Organization for Research and Treatment of Cancer-EORTC)

Principal Investigator or Co-Investigator for more than 20 trials (Industry-sponsored or Academic) dealing with Brain Tumors and Hepatocellular Carcinoma

January 2011- March 2014

University of Padua -

Public Hospital

PhD on Oncology and Oncological Surgery

Research of a biomarker in glioma patients

## EDUCATION AND TRAINING

- Dates (from – to)
- Name and address of employer
  - Type of business or sector
  - Occupation or position held
- Main activities and responsibilities

January 2011- March 2014

University of Padua -

Public Hospital

PhD on Oncology and Oncological Surgery

Research of a biomarker in glioma patients

- Dates (from – to)
- Name and type of organisation providing education and training
- Principal subjects/occupational skills covered
- Title of qualification awarded

2006-2010

Padova University

Medical Oncology

Specialty in Medical Oncology

- Dates (from – to)
- Name and type of organisation providing education and training
- Principal subjects/occupational skills covered
- Title of qualification awarded

2004

Padova University

Medicine

Degree in Medicine (M.D.-Medical Doctor)

## ACADEMIC POSITION

- Dates (from – to)
- Name and address of employer
  - Type of business or sector
  - Occupation or position held
- Main activities and responsibilities

January 2011- March 2014

University of Padua -

Public Hospital

PhD on Oncology and Oncological Surgery

Research of a biomarker in glioma patients

**PERSONAL SKILLS  
AND COMPETENCES**

*Acquired in the course of life and career  
but not necessarily covered by formal  
certificates and diplomas.*

MOTHER TONGUE

**ITALIAN**

OTHER LANGUAGES

**ENGLISH**

- Reading skills
- Writing skills
- Verbal skills

EXCELLENT

EXCELLENT

GOOD

OTHER LANGUAGES

**FRENCH**

- Reading skills
- Writing skills
- Verbal skills

GOOD

GOOD

GOOD

ORGANISATIONAL SKILLS  
AND COMPETENCES

*Coordination and administration of people,  
projects and budgets; at work, in voluntary  
work (for example culture and sports) and at  
home, etc.*

MANAGEMENT OF CANCER PATIENTS WITHIN MULTIDISCIPLINARY TEAMS

WRITING OF RESEARCH PROJECTS

CONDUCTION OF CLINICAL TRIALS (PHASE II, III AND IV)

TECHNICAL SKILLS  
AND COMPETENCES

*With computers, specific kinds of equipment,  
machinery, etc.*

OFFICE PACKAGE

RESEARCHES IN PUBLIC DATABASES

STATISTICAL SOFTWARE (SPSS )

ENDNOTE AND REFWORKS SOFTWARE (FOR PAPER EDITING)

PROMETA (META-ANALYSIS SOFTWARE)

**ANNEXES**

EDITORIAL MEMBER

BOOK

SCIENTIFIC PUBLICATIONS

SCIENTIFIC AFFILIATIONS

**Editorial Member**

Editorial Member of Translational Neuro-Oncology

Editorial Member of "Case Report in Urology" and "Journal of Tumor" and "Hepatoma Research" and "Journal of Cancer Metastasis and Treatment"

**Books**

**Lombardi G.** Italian Translation of "Neoplasm of the central nervous System" (Cap 97) and "Molecular Biology of Central Nervous System Tumors" (Cap 96). *Oncologia Principi e Pratica*. De Vita. 10<sup>th</sup> Italian edition.

F. Zustovich, **G. Lombardi**. *Glioblastoma Patients: Chemotherapy with Cisplatin, Temozolomide and Thalidomide*; M.A. Hayat (ed.), *Tumors of the Central Nervous System*, Volume 2, 255-260; © Springer Science+Business Media B.V. 2011

## Scientific Publications

Dr. Lombardi has numerous abstracts and published papers in peer reviewed journals, in particular on brain tumors

**Lombardi G**, Pambuku A, Bellu L, Farina M, Della Puppa A, Denaro L, Zagonel V. Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials. *Crit Rev Oncol Hematol*. 2017 Mar;111:94-102

**Lombardi G**, Della Puppa A, Zagonel V. Urine 2-Hydroxyglutarate in Glioma. *Oncologist*. 2016 Aug;21(8):1026. doi: 10.1634/theoncologist.2016-0123.

**Lombardi G**, Bellu L, Pambuku A, Della Puppa A, Fiduccia P, Farina M, D'Avella D, Zagonel V. Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study. *J Neurooncol*. (2016) Jul;128(3):481-6. doi: 10.1007/s11060-016-2136-7. Epub 2016 May 11.

**Lombardi G**, Pace A, Pasqualetti F, Rizzato S, Faedi M, Anghileri E, Nicolotto E, Bazzoli E, Bellu L, Villani V, Fabi A, Ferrazza P, Gurrieri L, Dall'Agata M, Eoli M, Della Puppa A, Pambuku A, D'Avella D, Berti F, Rudà R, Zagonel V. Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). *J Neurooncol*. (2015) Nov;125(2):359-67. doi: 10.1007/s11060-015-1923-x. Epub 2015 Sep 30.

**Lombardi G**, Corona G, Bellu L, Della Puppa A, Pambuku A, Fiduccia P, Bertorelle R, Gardiman MP, D'Avella D, Toffoli G, Zagonel V. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with IDH-mutated glioma. *The Oncologist*. In press 2015

Zustovich F, Ferro A, **Lombardi G**, Farina P, Zagonel V. Bevacizumab-Based Therapy for Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Preliminary Results. *Chemotherapy*. 2015 May 20;60(5):294-299. [Epub ahead of print]

**Lombardi G**, Di Stefano AL, Farina P, Zagonel V, Tabouret E. Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature. *Cancer Treat Rev*. (2014) Sep;40(8):951-9

**G. Lombardi**, F. Zustovich, P. Farina, A. Della Puppa, R. Manara, D. Cecchin, A. Brunello, A. Cappetta, V. Zagonel. Neoplastic Meningitis from Solid Tumors: New Diagnostic and Therapeutic Approaches. *The Oncologist* (2011); 16:1175-1188

**G. Lombardi**, F. Zustovich, F. Farinati, U. Cillo, A. Vitale, G. Zanusi, M. Donach, M. Farina, S. Zovato, D. Pastorelli. Pegylated liposomal Doxorubicin and Gemcitabine in Patients With Advanced Hepatocellular Carcinoma. *Cancer* (2011); 117: 125-33.

**G. Lombardi**, F. Zustovich, P. Farina, P. Fiduccia, A. Della Puppa, V. Polo, R. Bertorelle, M. P. Gardiman, A. Banzato, P. Ciccarino, L. Denaro, V. Zagonel. Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature. *Anti-Cancer Drug* (2013); 24:90-97

**G. Lombardi**, E. Ruminato, R. Bertorelle, D. Saggioro, P. Farina, A. Della Puppa, F. Zustovich, F. Berti, V. Sacchetto, R. Marcato, A. Amadori, V. Zagonel. Clinical and Genetic Factors Associated With severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment. A prospective study. *Am J Clin Onc* (2013); Sep 21 (Epub ahead of print). DOI: 10.1097/COC.0b013e3182a790ea

**G. Lombardi**, F. Zustovich, M. Donach, M. Dalla Palma, O. Nicoletto, D. Pastorelli. An update on targeted therapy in metastatic renal cell carcinoma. *Urologic Oncology: Seminars and Original Investigations* (2012); 30: 240-246

**G. Lombardi**, F. Zustovich, P. Farina, V. Polo, M. Farina, A. Della Puppa, R. Bertorelle, M. P. Gardiman, F. Berti, V. Zagonel. Cilengitide in bevacizumab-refractory high-grade glioma: two case reports and critical review of the literature. *Anti-Cancer Drugs* (2012); 23:749-753

**G. Lombardi**, M. O. Nicoletto, M. Gusella, P. Fiduccia, M. Dalla Palma, A. Zuin, D. Fiore, M. Donach, V. Zagonel. Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysis. *Cancer Chemother Pharmacol* (2012) 69:781-787

**G. Lombardi**, F. Zustovich, A. Della Puppa, L. Borgato, E. Orvieto, R. Manara, D. Cecchin, F. Berti, P. Farina, M. P. Gardiman, R. Scienza, V. Zagonel. Cisplatin and Temozolomide combination in the treatment of leptomeningeal carcinomatosis from ethmoid sinus intestinal-type adenocarcinoma. *J Neurooncol* (2011); 1041:381-386.

**G. Lombardi**, F. Zustovich, M. O. Nicoletto, M. Donach, G. Artioli, D. Pastorelli. Diagnosis and Treatment of Malignant Pleural Effusion. A systematic Literature Review and New Approaches. *American Journal of Clinical Oncology* (2010); 33:420-3.

Pasqualetti F, Orlandi P, Simeon V, Cantarella M, Giuliani D, Di Desidero T, Gonnelli A, Delishaj D, **Lombardi G**, Sechi A, Sanson M, Zagonel V, Paiar F, Danesi R, Guarini S, Bocci G. Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy. *Mol Neurobiol*. 2017 Feb 1.

Banzato A, Denas G, **Lombardi G**, Pambuku A, Bianchi A, Pengo V. The Three Players of Mechanical Valve Thrombosis: Cancer, Anticancer Therapy, and Thromboprophylaxis. *J Heart Valve Dis*. 2016 Jul;25(4):522-524.

Nicoletto MO, Casarin A, Baldoni A, Rulli E, Tasca G, Baretta Z, Artioli G, **Lombardi G**, Cappetta A, Floriani I, Randon G, Valpione S, Litta P, Conte P, Mocellin S, Aliberti C. Intraperitoneal Chemotherapy in Patients Pretreated for Ovarian Cancer Matched with Patients Treated with Parenteral Chemotherapy. *Anticancer Res*. 2016 Dec;36(12):6541-6546.

Della Puppa A, **Lombardi G**, Rossetto M, Rustemi O, Berti F, Cecchin D, Gardiman MP, Rolma G, Persano L, Zagonel V, Scienza R. Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up. *J Neurooncol*. 2016 Oct 18. [Epub ahead of print]

Maule F, Bresolin S, Rampazzo E, Boso D, Puppa AD, Esposito G, Porcù E, Mitola S, **Lombardi G**, Accordi B, Tumino M, Basso G, Persano L. Annexin 2A sustains glioblastoma cell dissemination and proliferation. *Oncotarget*. (2016) Jul 13. doi: 10.18632/oncotarget.10565. [Epub ahead of print].

Brandes AA, Finocchiaro G, Zagonel V, Reni M, Caserta C, Fabi A, Clavarezza M, Maiello E, Eoli M, **Lombardi G**, Monteforte M, Proietti E, Agati R, Eusebi V, Franceschi E. AVAREG: a phase 2, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. *Neuro Oncol*. (2016) Mar 6. pii: now035. [Epub ahead of print]

Mazza E, Brandes A, Zanon S, Eoli M, **Lombardi G**, Faedi M, Franceschi E, Reni M. Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). *Cancer Chemother Pharmacol*. (2016) Jan;77(1):115-20. doi: 10.1007/s00280-015-2927-0. Epub 2015 Dec

D. Pastorelli, F. Zustovich, G. Faggioni, S. Zovato, M. Donach, O. Nicoletto, M. Farina, L. Furini, R. Ceravolo, P. Carli, **G. Lombardi**. Good response to second-line bevacizumab and interferon- $\alpha$  in a sunitinib-refractory patient with metastatic renal cell carcinoma. *Anti-cancer Drugs* (2010) 21:210-213

**G. Lombardi**, F. Zustovich, MO Nicoletto, M. Donach, D. Pastorelli. Important role of thiamine in preventing ifosfamide-induced encephalopathy. *J Oncol Pharm Practice* (2010); 16: 135-136

**G. Lombardi**, F. Zustovich, S. Zovato, D. Fiore, A. Cappetta, D. Pastorelli. Characteristics and management of pancreatic lesion in Von Hippel-Lindau disease: a systematic literature review. *Oncol Rev* (2009); 3:103-106

**G. Lombardi**, A. Pambuku, L. Bellu, A. Della Puppa, L. Rumanò, M. P. Gardiman, F. Pomerri, V. Zagonel. Cisplatin and temozolomide combination in the treatment of supratentorial anaplastic ependymoma. *Chemotherapy* (2013) ; 31 :59(3):176-180. [Epub ahead of print]

Angiopoietin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma. Labussière M, Cheneau C, Prahst C, Gállego Pérez-Larraya J, Farina P, **Lombardi G**, Mokhtari K, Rahimian A, Delattre JY, Eichmann A, Sanson M. *Cancer Invest.* (2016);34(1):39-44. doi: 10.3109/07357907.2015.1088948. Epub 2016 Jan 6.

The calm before the storm: a report from the International Liver Cancer Association Congress 2015 - part 2. Cabibbo G, Reig M, Gadaleta-Caldarola G, Galati G, **Lombardi G**, Mazza G, Marzi L, Saitta C, Nault JC, Sacco R. *Future Oncol.* (2016) Feb;12(3):285-8. doi: 10.2217/fon.15.324. Epub 2016 Jan 18.

The calm before the storm: a report from the International Liver Cancer Association Congress 2015--part 1. Cabibbo G, Reig M, Gadaleta-Caldarola G, Galati G, **Lombardi G**, Mazza G, Marzi L, Saitta C, Nault JC, Sacco R. *Future Oncol.* (2016) Feb;12(3):281-4. doi: 10.2217/fon.15.323. Epub 2016 Jan 18

F. Zustovich, **G. Lombardi**, O. Nicoletto, D. Pastorelli. Second-line therapy for refractory renal-cell carcinoma. *Critical Reviews in Oncology/Hematology* (2012); 83:112-122.

Vitale, **G. Lombardi**, R. Ramirez Morales, U. Cillo. Potential impact of sorafenib on the survival benefit of liver transplantation for hepatocellular carcinoma. *Digestive and Liver Disease* (2012); 44: 361-362.

F. Zustovich, **G. Lombardi**, P. Farina. Treating patients with metastatic renal carcinoma: an escape from Phase III. *Expert Rev. Anticancer Ther.* (2012); 12(7): 919-927.

F. Zustovich, **G. Lombardi**, D. Pastorelli, P. Farina, L. Furini, R. Manara, M. Dalla Palma, A. Rotilio, O.Nicoletto, V. Zagonel. Bevacizumab and Glioblastomas, a Single-Centre Experience: How Disease History and Characteristics May Affect Clinical Outcome. *Anticancer Research* (2010); 30:5213-5216.

M. Dalla Palma, **G. Lombardi**, M.E. Donach, L.Borgato, F. Zustovich, L. Furini, M. O. Nicoletto. Tolerability of PLD/Oxaliplatin Regimen in Recurrent Ovarian Cancer Patients With Previous Fragility to Carboplatin/Paclitaxel treatment. *Am J Clin Onc* (2011); 34(3): 305-8.

Zustovich F., **Lombardi G.**, Cartei G. Paraneoplastic diffuse cutaneous papillomatosis. *J Eur Acad Dermatol Venerol* (2009); 23(2): 220-

F. Zustovich, **G. Lombardi**, D. Pastorelli. Important role of gemcitabine in the treatment of classic Kaposi's sarcoma. *Tumori* (2009); 95: 562-563.

F. Zustovich, **G. Lombardi**, A. Della Puppa, A. Rotilio, R. Scienza, D. Pastorelli. A Phase II Study of Cisplatin and Temozolomide in Heavily Pre-treated Patients with Temozolomide-refractory High-grade Malignant Glioma. *Anticancer Research* (2009); 23:4275-4280.

F. Zustovich, **G. Lombardi**, N. Amirouchene, D. Pastorelli. Adult high-grade malignant gliomas. *Oncol Rev* (2008) 2:233-237.

F. Zustovich, A. Ferro, **G. Lombardi**, V. Zagonel, P. Fiduccia, P. Farina. Bevacizumab as Front-line Treatment of Brain Metastases from Solid Tumors: A Case Serie. *Anticancer Research* (2013); 33:4061-4066.

P. Farina, **G. Lombardi**, M. Rossetto, A. Alentorn, M. Sanson. Oligodendroglial tumors: from biology to a better patient care. *Reviews in Oncology* (2013); 1 (1): 15-20.

F. Zustovich, L. Landi, **G. Lombardi**, C. Porta, L. Galli, A.Fontana, D. Amoroso, C. Galli, M. Andreuccetti, A. Falcone, V. Zagonel. Sorafenib plus Daily Low-dose Temozolomide for Relapsed Glioblastoma: A Phase II Study. *Anticancer Research* (2013); 33:3487-3494.

Della Puppa, S. De Pellegrin, E. D'Avella, G. Giofrè, M. Rossetto, A. Gerardi, **G. Lombardi**, R. Manara, M. Munari, M. Saladini, R. Scienza. 5-aminolevulinic acid (5-ALA) fluorescence guided surgery of high-grade gliomas in eloquent areas assisted by functional mapping. Our experience and review of the literature. *Acta Neurochir* (2013) 155:965-972.

Cappetta, S. Lonardi, D.Pastorelli, F. Bergamo, **G. Lombardi**, V. Zagonel. Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies. *Critical Reviews in Oncology/Hematology* 81 (2012) 38-48.

Vitale, P. Boccagni, X. Kertusha, G. Zanus, F. D'Amico, E. Lodo, D. Pastorelli, R. Ramirez Morales, **G. Lombardi**, M. Senzolo, P. Burra, U. Cillo. Sorafenib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplantation?. *Transplantation Proceedings* (2012); 44, 1989-1991

P. Ciccarino, A. Rotilio, M. Rossetto, R. Manara, E. Orvieto, F. Berti, **G. Lombardi**, D. D'Avella, R. Scienza, A. Della Puppa. Multifocal presentation of medulloblastoma in adulthood. *J Neurooncol* (2012) 107:233-237.

F. Zustovich, **G. Lombardi**, D. Pastorelli, P. Farina, M. Dal Bianco, L. De Zorzi, M. Dalla Palma, O. Nicoletto, V. Zagonel. Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma. *Open Access Journal of Urology* (2011); 3: 69-82

G. Artioli, M. Cassaro, L. Pedrini, L. Borgato, L. Corti, A. Cappetta, **G. Lombardi**, M.O. Nicoletto. Rare presentation of endometrial carcinoma with singular bone metastasis. *European Journal of Cancer Care* (2010); 19, 694-698.

M.O. Nicoletto, A. Parenti, P. Del Bianco, **G. Lombardi**, L. Pedrini, S. Pizzi, P. Carli, M. Della Palma, D.Pastorelli, L. Corti, L. Becagli. Vulvar Cancer: Prognostic Factors. *Anticancer Research* (2010); 30:2311-2318.

M. O. Nicoletto, R. Bertorelle, L. Borgato, G. L. De Salvo, G. Artioli, **G. Lombardi**, F. Zustovich, R. Marcato, A. Parenti, M. Montagna, M. E. Donach. Family History of Cancer Rather Than p 53 Status Predicts Efficacy of Pegylated liposomal Doxorubicin and Oxaliplatin in Relapsed Ovarian Cancer. *Int J Gynecol Cancer* (2009); 19 (6): 1022-8.

F. Zustovich, M. Shams, P. Anselmi, **G. Lombardi**, D. Pastorelli, G. Cartei. Cognitive and emotive state in elderly treatment-naive patients with advanced cancer compared with an elderly healthy control population. *Cancer Therapy Vol 7* (2009) 149-154

Colombatti R., Calò A., Iacopetti T., Rosolen A., **Lombardi G.**, Cesaro S. Successful treatment of Severe Iatrogenic Calcinosis Cutis with Intravenous Sodium Thiosulfate in a Child Affected by T-Acute Lymphoblastic Leukemia. *Pediatric Dermatology* (2009) Vol. 26 No. 3 311-315

F. Ceccato, G. Occhi, D. Regazzo, M.L. Randi, D. Cecchin, M. P. Gardiman. R. Manara, **G. Lombardi**, L. Denaro, F. Mantero, C. Scaroni. Gonadotropin secreting pituitary adenoma associated with erythrocytosis: case report and literature review. *Hormones* (2014), 13(1): 131-139

Della Puppa A, Rustemi O, Giofrè G, Troncon I, **Lombardi G**, Rolma G, Sergi M, Munari M, Cecchin D, Gardiman MP, Scienza R. Predictive value of intraoperative 5-aminolevulinic acid-induced fluorescence for detecting bone invasion in meningioma surgery. *J Neurosurgery* 2014 Jan 10 (epub ahead of print)

D. Cecchin, I. Schiorlin, A. Della Puppa, **Lombardi G.** et al, Assessing Response Using -MIBI Early after Interstitial Chemotherapy with Carmustine-Loaded Polymers in Glioblastoma Multiforme: Preliminary Results, *BioMed Research International*, vol. 2014, Article ID 684383, 6 pages, 2014. doi:10.1155/2014/684383

**Lombard Gi**, Patrizia Farina, Alessandro Della Puppa, et al., An Overview of Fotemustine in High-Grade Gliomas: From Single Agent to Association with Bevacizumab, *BioMed Research International*, vol. 2014, Article ID 698542, 8 pages, 2014. doi:10.1155/2014/698542

**Lombardi G.**, Alessandro Della Puppa, Fable Zustovich, et al., "The Combination of Carmustine Wafers and Fotemustine in Recurrent Glioblastoma Patients: A Monoinstitutional Experience, *BioMed Research International*, vol. 2014, Article ID 678191, 4 pages, 2014. doi:10.1155/2014/678191

Alessandro Della Puppa, Pietro Ciccarino, **Giuseppe Lombardi**, Giuseppe Rolma, Diego Cecchin, and Marta Rossetto. 5-Aminolevulinic Acid Fluorescence in High Grade Glioma Surgery: Surgical Outcome, Intraoperative Findings, and Fluorescence Patterns, *BioMed Research International*, vol. 2014, Article ID 232561, 8 pages, 2014. doi:10.1155/2014/232561

Patrizia Farina, **Giuseppe Lombardi**, Eleonora Bergo, Anna Roma, Vittorina Zagonel. Treatment of malignant gliomas in elderly patients: a concise overview of the literature. *BioMed Research International*, vol. 2014, Article ID 734281, 9 pages, 2014. doi: 10.1155/2014/734281

Sacco R, Gadaleta-Caldarola G, Galati G, **Lombardi G**, Mazza G, Cabibbo G. EASL HCC summit: liver cancer management. *Future Oncol.* (2014) May;10(7):1129-32

Touat M, **Lombardi G**, Farina P, Kalamarides M, Sanson M. Successful treatment of multiple intracranial meningiomas with the antiprogestosterone receptor agent mifepristone (RU486). *Acta Neurochir (Wien)* (2014) Jul 31. [Epub ahead of print]

**Lombardi G**, Della Puppa A, Di Stefano AL, Pace A, Rudà R, Tabouret E, Zagonel V. Gliomas. *Biomed Res Int.*(2014). Epub 2014 Aug 26.

Sacco R, Gadaleta-Caldarola G, Galati G, **Lombardi G**, Mazza G, Cabibbo G. European Association for the Study of the Liver Hepatocellular Carcinoma summit 2014: old questions, new (or few) answers? *Future Oncol.* 2014 Aug;10(10):1719-21. doi: 10.2217/fo.14.102.

Di Stefano AL, Labussiere M, **Lombardi G**, Eoli M, Bianchessi D, Pasqualetti F, Farina P, Cuzzubbo S, Gallego-Perez-Larraya J, Boisselier B, Ducray F, Cheneau C, Moglia A, Finocchiaro G, Marie Y, Rahimian A, Hoang-Xuan K, Delattre JY, Mokhtari K, Sanson M. VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab. *J Neurooncol.* 2014 Dec 7. [Epub ahead of print]

Ceccato F, **Lombardi G**, Manara R, Emanuelli E, Denaro L, Milanese L, Gardiman MP, Bertorelle R, Scanarini M, D'Avella D, Occhi G, Boscaro M, Zagonel V, Scaroni C. Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center. *J Neurooncol.* 2015 Mar;122(1):189-96.

Losa M, Bogazzi F, Cannavo S, Ceccato F, Curtò L, De Marinis L, Iacovazzo D, **Lombardi G**, Mantovani G, Mazza E, Minniti G, Nizzoli M, Reni M, Scaroni C Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. *J Neurooncol.* (2016) Feb;126(3):519-25. doi: 10.1007/s11060-015-1991-y. Epub 2015 Nov 27.

Della Puppa A, d'Avella E, Rossetto M, Volpin F, Rustemi O, Giofrè G, **Lombardi G**, Rolma G, Scienza R Open trans-cranial resection of small (<35mm) meningiomas of the anterior midline skull base in current microsurgical practice. *World Neurosurg.* 2015 May 6.

#### Scientific affiliations

ITALIAN ASSOCIATION OF MEDICAL ONCOLOGY-**AIOM**

EUROPEAN SOCIETY OF MEDICAL ONCOLOGY-**ESMO**

AMERICAN SOCIETY OF MEDICAL ONCOLOGY-**ASCO**

EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY- **EANO**

EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER (EORTC) – **BRAIN TUMOR GROUP**

ASSOCIAZIONE ITALIANA DI NEURO-ONCOLOGIA - **AINO**